Oral Session 3-12D MPN: Clinical

[OS3-12D-2] Comparison of outcomes of allogeneic HSCT for primary myelofibrosis among stem cell source groups

Makoto Murata^1,11, Katsuto Takenaka^2,11, Naoyuki Uchida³, Yukiyasu Ozawa⁴, Kazuteru Ohashi⁵, Sung-Won Kim⁶, Kazuhiro Ikegame⁷, Makoto Hirokawa⁸, Takahiro Fukuda⁶, Yoshiko Atsuta⁹, Takeshi Kondo^10,11 (1.Hematology and Oncology, Nagoya University, Nagoya, Japan, 2.Hematology, Clinical Immunology and Infectious Diseases, Ehime University, Toon, Japan, 3.Hematology, Toranomon Hospital, Tokyo, Japan, 4.Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 5.Hematology, Komagome Hospital, Tokyo, Japan, 6.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 7.Hematology, Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 8.General Internal Medicine and Clinical Laboratory Medicine, Akita University, Akita, 9.Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan, 10.Hematology, Aiiku Hospital, Sapporo, Japan, 11.Adult CML/MPN Working Group, JSHCT, Japan)